Cisplatin and Irinotecan (CPT-11) for Peritoneal Mesothelioma

References

• Markman M., Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J. Cancer Res. Clin. Oncol. 1992; 118(7)547–550
   PubMed Web of Science ®Google Scholar
• Verschraegen C., Mansfield P., Feig B., Steger M., Wu Q., MacLean D., Siddik Z., Perez-Soler R., Hu W., Kudelka A., Kavanagh J., Khokhar A. Phase I study of an intraperitoneal liposomal cisplatin analog l-nddp for treatment of peritoneal carcinomatosis. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 1999; 18: A1405
   Google Scholar
• Mintzer D.M., Kelsen D., Frimmer D., Heelan R., Gralla R. Phase II trial of high-dose cisplatin in patients with malignant mesothelioma. Cancer Treat. Rep. 1985; 69(6)711–712
   PubMedGoogle Scholar
• Noda W., Nishiwaki Y., Kawahara M., Negoro S., Sugiura T., Yokoyama A., Fukuoka M., Mori K., Watanabe K., Tamura T., Yamamoto S., Saijo N. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. New Engl. J. Med. 2002; 346(2)85–91
   PubMed Web of Science ®Google Scholar
• Adachi S., Ogasawara T., Yamasaki N., Shibahara H., Kanazawa R., Tsuji Y., Takemura T., Koyama K. A pilot study of CPT-11 and cisplatin for ovarian clear cell adenocarcinoma. Jpn. J. Clin. Oncol. 1999; 29(9)434–437
   PubMed Web of Science ®Google Scholar
• Boku N., Ohtsu A., Shimada Y., Shirao K., Seki S., Saito H., Sakata Y., Hyodo I. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J. Clin. Oncol. 1999; 17(1)319–323
   PubMed Web of Science ®Google Scholar
• Ilson D.H., Saltz L., Enzinger P., Huang Y., Kornblith A., Gollub M., O'Reilly E., Schwartz G., DeGroff J., Gonzalez G., Kelsen D.P. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J. Clin. Oncol. 1999; 17(10)3270–3275
   PubMed Web of Science ®Google Scholar
• Sugiyama T., Yakushiji M., Noda K., Ikeda M., Kudoh R., Yajima A., Tomoda Y., Terashima Y., Takeuchi S., Hiura M., Saji F., Takahashi T., Umesaki N., Sato S., Hatae M., Ohashi Y. Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer. Oncology 2000; 58(1)31–37
   PubMed Web of Science ®Google Scholar
• Nakano T., Chahinian A.P., Shinjo M., Togawa N., Tonomura A., Miyake M., Ninomiya K., Yamamoto T., Higashino K. Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile. Cancer 1999; 85(11)2375–2384
   PubMed Web of Science ®Google Scholar
• Lederman G.S., Recht A., Herman T., Osteen R., Corson J., Antman K.H. Combined modality treatment of peritoneal mesotheliomas. NCI Monogr. 1988; 6: 321–322
   PubMedGoogle Scholar
• Ma G.Y., Bartlett D.L., Reed E., Figg W.D., Lush R.M., Lee K.B., Libutti S.K., Alexander H.R. Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma. Cancer J. Sci. Am. 1997; 3(3)174–179
   PubMed Web of Science ®Google Scholar
• Sebbag G., Yan H., Shmookler B.M., Chang D., Sugarbaker P.H. Results of treatment of 33 patients with peritoneal mesothelioma. Br. J. Surg. 2000; 87(11)1587–1593
   PubMed Web of Science ®Google Scholar
• Ball D., Cruickshank D. The treatment of malignant mesothelioma of the pleura: review of a 5-year experience, with special reference to radiotherapy. Am. J. Clin. Oncol. 1990; 13: 4–9
   PubMed Web of Science ®Google Scholar
• Gordon W., Antman K., Greenberger J., Weichselbaum R., Chaffey J. Radiation therapy in the management of patients with mesothelioma. Int. J. Rad. Oncol. Biol. Phys. 1982; 8: 19–25
   PubMed Web of Science ®Google Scholar
• Taub R.N., Antman K.H. Chemotherapy for malignant mesothelioma. Semin. Thor. Cardiovasc. Surg. 1997; 9(4)361–366
   PubMedGoogle Scholar
• Kindler H.L., Millard F., Herndon J.E., II, Vogelzang N.J., Suzuki Y., Green M.R. Gemcitabine for malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B. Lung Cancer 2001; 31(2–3)311–317
   PubMed Web of Science ®Google Scholar
• Taub R., Keohan M.L., Vogelzang N.J., Costanzi J., Chun H., Mittelman A., Panella T., McCachren S., Puccio C., Shogen K., Fine R., Mikulski S.M. Phase II trial of onconase (onc) in patients (pts) with advanced malignant mesothelioma (mm): analysis of survival. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 1999; 18: A2021
   Google Scholar
• Le Chevallier T. Multi-targeted antifolate therapy for non-small cell lung cancer and mesothelioma. Anti Cancer Drugs 2001; 12(3)21–25
   PubMedGoogle Scholar
• Tsunoda T., Tanimura H., Hotta T., Tani M., Iwahashi M., Ishimoto K., Tanaka H., Matsuda K., Yamaue H. In vitro augmentation of antitumor effect in combination with CPT-11 and CDDP for human colorectal cancer. J. Surg. Oncol. 2000; 73(1)6–11
   PubMed Web of Science ®Google Scholar
• Kanzawa F., Nishio K., Fukuoka K., Fukuda M., Kunimoto T., Saijo N. Evaluation of synergism by a novel three-dimensional model for the combined action of cisplatin and etoposide on the growth of a human small-cell lung-cancer cell line, SBC-3. Int. J. Cancer 1997; 71(3)311–319
   PubMed Web of Science ®Google Scholar
• Goldwasser F., Valenti M., Torres R., Kohn K.W., Pommier Y. Potentiation of cisplatin cytotoxicity by 9-aminocamptothecin. Clin. Cancer Res. 1996; 2(4)687–693
   PubMed Web of Science ®Google Scholar
• Albain K.S., Swinnen L.J., Erickson L.C., Stiff P.J., Fisher S.G., Fisher R.I. Cytotoxic synergy of cisplatin with concurrent hydroxyurea and cytarabine: summary of an in vitro model and initial clinical pilot experience. Sem. Oncol. 1992; 19(3 Suppl 9)102–109
   PubMed Web of Science ®Google Scholar
• Shin D., Fossella F., Umawasdi T. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant peritoneal mesothelioma. Cancer 1995; 76: 2230–2236
   PubMed Web of Science ®Google Scholar
• Markman M. Intraperitoneal chemotherapy: a rational approach to overcome drug resistance. Clinical Management of the Drug resistant Cancer Patient: New Options in Clinical Oncology, R.A. Nagourney, K.M., Sheikh. Memorial Medical Center Foundation, Long Beach, CA 1991; 85–105
   Google Scholar
• Alberts D.S., Liu P.Y., Hannigan E.V., O'Toole R., Williams S.D., Young J.A., Franklin E.W., Clarke-Pearson D.L., Malviya V.K., DuBeshter B. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Eng. J. Med. 1996; 335(26)1950–1955
   PubMed Web of Science ®Google Scholar
• Takiyama I., Terashima M., Ikeda K., Kawamura H., Sasaki N., Hayakawa Y., Ishida K., Saito K. Remarkable synergistic interaction between camptothecin analogs and cisplatin against human esophageal cancer cell lines. Proc. Annu. Meet. Am. Assoc. Cancer Res. 1997; 38: A101
   Google Scholar
• Verschraegen C., Le D., Kudelka A., Kavanagh J., Hunt K.J. Cisplatin and irinotecan for peritoneal mesothelioma. Proc. Am. Soc. Clin. Oncol. 2001; 20: A2110
   Google Scholar
• Azevedo P., Verschraegen C.F., Kavanagh J.J., Kudelka A.P., Freedman R.S., Lu K., Deavers M.T. Malignant mixed mesodermal tumor of the ovary treated with a cisplatin-irinotecan combination: case report. Eur. J. Gynaecol. Oncol. 2001; 22(5)319–321
   PubMed Web of Science ®Google Scholar
• Verschraegen C.F., Levy T., Kudelka A.P., Llerena E., Ende K., Freedman R.S., Edwards C.L., Hord M., Steger M., Kaplan A.L., Kieback D., Fishman A., Kavanagh J.J. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J. Clin. Oncol. 1997; 15(2)625–631
   PubMed Web of Science ®Google Scholar
• Balat O., Verschraegen C. Topoisomerase I inhibitors in gynecologic cancers. Expert Opin. Investig. Drugs 1995; 4: 1217–1230
   Google Scholar
• Vlasveld L.T., Gallee M.P., Rodenhuis S., Taal B.G. Intraperitoneal chemotherapy for malignant peritoneal mesothelioma. Eur. J. Cancer 1991; 27(6)732–734
   PubMed Web of Science ®Google Scholar
• Langer C.J., Rosenblum N., Hogan M., Nash S., Bagchi P., LaCreta F.P., Catalano R., Comis R.L., O'Dwyer P.J. Intraperitoneal cisplatin and etoposide in peritoneal mesothelioma: favorable outcome with a multimodality approach. Cancer Chemother. Pharmacol. 1993; 32(3)204–208
   PubMed Web of Science ®Google Scholar